Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
OSTX
OS Therapies Incorporated
NYSE AMERICAN
Biotechnology
United States
$1.88
▲
+0.06 (+3.30%)
POST
—
OPEN
$1.84
HIGH
$1.96
LOW
$1.84
PREV CLOSE
$1.82
VOLUME
982.2K
1.78x avg
BID / ASK
1.88 / 1.90
spr 0.020
MARKET CAP
$87.4M
DAY RANGE
$1.84
$1.96
P/E (TTM)
—
Fwd 5.8
EPS (TTM)
-1.09
DIV YIELD
—
52W HIGH
$2.35
-20.0%
52W LOW
$1.15
+63.5%
BETA
-0.68
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$1.92
+0.04
(+2.13%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
OSTX
$1.88
▲
+3.30%
Chart
Valuation
Financials
Peers
News
OSTX · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-OFF
252 BARS · -14.5% YOY
1-year price chart. Started at 2.20, currently 1.88, down 14.5 percent. Range 1.16 to 2.31 over 252 data points.
2025-09-05
$2.20 → $1.88 (-14.5%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
Peers:
FBIO PE1
ACET
RLYB PE2
ICCC PE141
ALDX
KLRS
GOSS
CRDF
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$28.8M
-$14.2M
-$14.7M
$6.8M
2024-12
—
-$8.9M
-$7.3M
—
$5.5M
2023-12
—
-$7.8M
-$3.0M
—
$798.1K
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
FBIO
ACET
RLYB
ICCC
ALDX
KLRS
GOSS
CRDF
MAIA
IBIO
NEWS
Recent News (past 14 days)
CALM
9 HEADLINES · LAST 14 DAYS
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
TMX Newsfile · 2026-09-02
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
TMX Newsfile · 2026-08-17
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
TMX Newsfile · 2026-08-13
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
TMX Newsfile · 2026-07-08
OS Therapies Third Quarter 2026 Corporate Outlook
TMX Newsfile · 2026-07-06
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
TMX Newsfile · 2026-07-02
OS Therapies Provides U.S. Regulatory Update
TMX Newsfile · 2026-06-30
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
TMX Newsfile · 2026-06-26